Dutch multiple myeloma diagnostic

able to guide treatment

ROTTERDAM (the Netherlands) and SAN DIEGO (US), November 28, 2018: an international consortium of researchers and physicians is the first to distinguish three risk groups in multiple myeloma (ultra-low, intermediate and high-risk patients) and show a favorable and distinct treatment strategy for the low and high-risk patients in an interim data analysis. Low risk patients eligible for autologous stem cell transplantation (ASCT) show improved outcomes on a non-transplant treatment strategy (95% versus 72% of patients alive after 4 years). The high-risk patients eligible for ASCT show improved outcomes on a transplant treatment strategy (68% versus 22% of patients alive after 4 years). The results are presented at the ASH Annual Meeting 2018 starting on December 1st in San Diego (US) [1].


The European Myeloma Network consortium used a combination of ISS (International Staging System), cytogenetic information (del17p) and the Dutch diagnostic test MMprofilerTM with the SKY92 marker to risk-stratify patients in the EMN-02/HOVON-95 trial. Upfront high dose melphalan (HDM) followed by ASCT (transplant strategy) is superior to bortezomib, melphalan & prednisone (VMP) without ASCT (non-transplant strategy). However, HDM causes damage in healthy cells and may induce growth of treatment resistant tumor cells. “Especially in low-risk patients, where the cancer is genetically less aggressive, HDM can be considered too combative, exposing the patient to unnecessary side effects and risk of resistance,” explains Dharminder Chahal, CEO of SkylineDx that developed the MMprofilerTM with SKY92 marker. “To give these patients more time with their family in better health, is incredibly humbling.”


“We are excited to have new data on this important congress supporting its value for multiple myeloma patients”, continues Dharminder Chahal. “Our MMprofilerTM is further internationally recognized as two highly respected research institutes in Ireland and Australia are independently including the diagnostic in their clinical studies, including in a novel agent setting with daratumumab, presenting their interim results at ASH as well [2-3]. Another demonstration of the added benefit of gene expression to guide an individual treatment plan”, concludes Dharminder Chahal.



  1. Hofste op Bruinink, et al. 2018. ASH Abstract 3186 (link). Poster presentation at ASH on Sunday, December 2, 2018, 6-8PM, Hall GH (San Diego Convention Center).
  2. Henderson, et al. 2018. ASH Abstract 3242 (link). Poster presentation at ASH on Sunday, December 2, 2018, 6-8PM, Hall GH (San Diego Convention Center).
  3. Spencer, et al. 2018. ASH Abstract 3279 (link). Poster presentation at ASH on Sunday, December 2, 2018, 6-8PM, Hall GH (San Diego Convention Center).


About SkylineDx
SkylineDx is a high-tech commercial-stage biotech company headquartered in Rotterdam, the Netherlands and a commercial office and laboratory in San Diego, California, USA. The company uses its expertise to bridge the gap between academically discovered gene expression signatures and commercially available diagnostic products with high clinical utility. With the focus on diagnostics, SkylineDx assists healthcare professionals in accurately determining the type or status of the disease or to predict a patient’s response to a specific treatment. Based on the test results, healthcare professionals can tailor the treatment to the individual patient. To learn more, please visit www.skylinedx.com.

Our news

Dutch government grants €2.7M for development skin cancer test

  ROTTERDAM (the Netherlands) and SAN DIEGO (US), September 27, 2018: Netherlands Enterprise Agency (“Rijksdienst voor Ondernemend Nederland”), a part of the Ministry of Economic Affairs and Climate Policy, grants through a

read more

Nederlandse overheid financiert € 2,7M voor ontwikkeling huidkankertest

  ROTTERDAM en SAN DIEGO (USA), 27 september, 2018: Rijksdienst voor Ondernemend Nederland (RVO), een onderdeel van het ministerie van Economische Zaken en Klimaat, kent, middels Innovatiekrediet, € 2,7 miljoen toe aan de ontwikkeling van

read more

Groundbreaking algorithm predicts best treatment for cancer patient

  ROTTERDAM, the Netherlands and SAN DIEGO USA, July 30th, 2018: Renowned scientific journal Nature Communications published July 27th, 2018 a research paper by Joske Ubels on the algorithm GESTURE [1] that links individual cancer patients to

read more

Baanbrekend algoritme voorspelt beste behandeling kankerpatiënt

  ROTTERDAM en SAN DIEGO (USA), 30 juli, 2018: Wetenschappelijk tijdschrift Nature Communications publiceerde 27 juli 2018 het onderzoekspaper van Joske Ubels over het GESTURE [1] algoritme dat individuele kankerpatiënten koppelt aan een

read more

Machine learning algorithm predicts treatment response in MM

  ROTTERDAM, the Netherlands and SAN DIEGO, USA, August 1, 2018: Renowned scientific journal Nature Communications published July 27th, 2018 a research paper by Joske Ubels about a novel machine learning concept that derives predictive

read more

SkylineDx Poster Presentations at EHA Meeting Further Validate Use of MMprofilerTM with SKY92 in Multiple Myeloma

  SKY92 risk stratification at relapse provides additional prognostic information for standardrisk Multiple Myeloma patients   RNA-Seq based risk stratification in Multiple Myeloma patients validates SKY92 as a high-risk marker in the

read more

SkylineDx Inks Joint Development Agreement with Mayo Clinic to Develop Diagnostic Tests for Melanoma

  Rotterdam, the Netherlands, January 31, 2018 – SkylineDx today announced a strategic collaboration with Mayo Clinic to develop novel diagnostic tests which will improve clinical decision making for melanoma patients. For SkylineDx, the

read more

SkylineDx Poster Presentations at ASH Meeting Further Validate Use of MMprofiler with SKY92 in Multiple Myeloma

  First Validation of SKY92 Prognostic Signature in Bortezomib-Thalidomide-Dexamethasone (VTD) Setting   Additional Data Yield Key Insights into Biology of Multiple Myeloma and Inform Design of Myeloma UK (MUK) Nine OPTIMUM Trial

read more

SKY92 Gene Signature Facilitates Cost-effective, Risk-stratified Treatment of Multiple Myeloma

  Poster Presentation at ISPOR European Congress Demonstrates Cost-savings and HealthGenerating Benefits of SKY92   Rotterdam, the Netherlands and Laguna Hills, CA, November 13, 2017 – SkylineDx announced new data from the 20th

read more

SkylineDx Announces Prognostic Tool to be Used as Part of Major New Myeloma Clinical Trial

  ICR to Use SkylineDx’s MMprofiler™ Gene-Based Prognostic Signature in Phase IIb MUK nine High-risk Trial in Multiple Myeloma   Rotterdam, the Netherlands and Laguna Hills, CA, October 12, 2017 – SkylineDx today

read more

SkylineDx Researchers Publish Data Demonstrating Utility of SKY92 as Prognostic Tool in Multiple Myeloma (MM)

  Clinical Lymphoma, Myeloma and Leukemia Paper Validates Use of SKY92 and its Combination with International Staging System (ISS)   Rotterdam, the Netherlands and Laguna Hills, CA, July 25, 2017 – SkylineDx today announced the

read more

SkylineDx Presented New Algorithm Demonstrating Ability to Successfully Identify Gene Sets that are Informative of Cancer Treatment Specific Survival

  Presentation at BioSB 2017 Demonstrated Value of GESTURE™ for Identifying Patient Subgroups Likely to Benefit from Anti-Cancer Treatment   Rotterdam, the Netherlands and Laguna Hills, CA, April 10, 2017 – SkylineDx

read more

SkylineDx Announces Multiple Studies Being Presented at the 58th Annual ASH Meeting Reinforcing Utility of MMprofiler™ Gene-Based Prognostic Signature to Impact Treatment of Patients with Multiple Myeloma

  New Studies Demonstrate Value of Gene Expression Risk Profiling to Identify Ultra-High-Risk Multiple Myeloma Patients   Rotterdam, the Netherlands and Laguna Hills, CA, November 29, 2016 – SkylineDx today announced the

read more

SkylineDx Receives Notice of Allowance to Grant Patent for Prognostic SKY92 Gene Signature in Japan

  The Japanese Patent Office Has Notified SkylineDx of the Decision to Grant a Patent for the SKY92 Gene Signature   Rotterdam, the Netherlands, Laguna Hills, CA, Tokyo, Japan, October 11, 2016 - SkylineDx is pleased to announce

read more

SkylineDx and Consortium of Leading European Partners awarded multi-million Euro Horizon2020 grant from European Commission

  Project Focuses on Development of Gene Expression Profiling Tool to Predict Treatment Outcomes for Patients with Multiple Myeloma   Rotterdam, the Netherlands and Laguna Hills, CA, October 4, 2016 - SkylineDx today announced

read more

SkylineDx to Present New Data Demonstrating MMprofiler™ as Robust Prognostic Tool in Multiple Myeloma at the European Hematology Association 21st Annual Congress (EHA)

  Studies Support Validity of SKY92 as a Superior Predictor of Risk Stratification in Newly Diagnosed and Relapsed Patients   Rotterdam, the Netherlands and Laguna Hills, CA, May 31, 2016 - SkylineDx today announced the

read more

SkylineDx Supports Myeloma Awareness Month to Raise Awareness of a Serious and Difficult to Treat Disease

  ROTTERDAM, Netherlands and LAGUNA HILLS, Calif., March 8, 2016 -- SkylineDx today announces its support for Myeloma Awareness Month, an effort conducted throughout the month of March by the International Myeloma Foundation (IMF) to

read more

SkylineDx to Present New Data Demonstrating Prognostic Value of MMprofiler™ in Multiple Myeloma at American Society of Hematology Annual Meeting

  Studies Support Use of MMprofiler™ for Stratifying High and Low-Risk in Newly Diagnosed Elderly and Relapsed Patients   MassGen Poster Highlights Use of MMprofiler™ in Phase II Modified RVD

read more

SkylineDx Receives CE-IVD Mark for MMprofiler™ -- Its Innovative Gene Signature-Based Test for Multiple Myeloma

  CE-IVD Approval Marks SkylineDx’s European Commercialization of its MMprofiler technology   Rotterdam, the Netherlands and Laguna Hills, CA, November 25, 2015 – SkylineDx, today announced they have received CE-IVD

read more

SKY92-ISS Superior to current markers in risk classification for myeloma survival

  Article in Blood shows the reliability of SKY92 genetic subtyping signature for prediction of disease progress for multiple myeloma (bone marrow cancer) patients   Rotterdam, the Netherlands, 8 September 2015 – Researchers at

read more

SkylineDx appoints Leonard Kruimer as CFO Peter Schineller as CCO

  Key additions to the management team as SkylineDx accelerates its development of gene signature-based diagnostics and prepares for the launch of its first product   Rotterdam, The Netherlands, 19 August 2015 - SkylineDx, a

read more

More Accurate Prediction on Prognosis in Multiple Myeloma (bone marrow cancer)

  Test of Dutch-based SkylineDx gives patients better insight in their chances and enables clinicians to adjust their treatment   Rotterdam, 2 July 2015 – SkylineDx, an innovative biotechnology company specialising in the

read more

SkylineDx Presents an Abstract on Risk Identification for Multiple Myeloma Patients at the 20th Congress of the EHA

  Boston (U.S.) – Rotterdam (NL), June 8, 2015. On the 13th of June SkylineDx will present an abstract detailing the comparison of SKY92 GEP, IFISH AND ISS for risk identification in Multiple Myeloma (MM) patients and the clinical

read more

Upcoming events

FEB 27-3, Washington DC, US: Dermatology Nurses' Association 2019

The Dermatology Nurses’ Association is a professional nursing organization comprised of a diverse group of individuals committed to quality care through sharing knowledge and expertise. The core purpose of the DNA is to promote excellence in

MAR 1-5, Washington DC, US: American Academy of Dermatology Annual Meeting

2019 American Academy of Dermatology (AAD) Annual Meeting is organized by American Academy of Dermatology (AAD) and will be held from Mar 01 - 05, 2019 at Walter E. Washington Convention Center, Washington, Dist of Col, United States of America.

MAR 5-6, Stockholm, Sweden: Elixir SME Forum

The Swedish and Finnish ELIXIR nodes are co-organizing an ELIXIR Innovation and SME Forum with a focus on Genomics and Associated Data in National Healthcare Initiatives March 5–6 together with Scilifelab Stockholm.

MAR 24-27, Frankfurt, Germany: European Society for Blood and Marrow Transplantation

The EBMT scientific council, together with the local organising committee, has designed an outstanding programme to cover key issues relating to HSCT and cellular therapy research. The programme is made up of more than 170 sessions and 300 speakers.

APR 4-5, Austria: World Congress on Advanced Treatments and Technologies in Skin Cancer

Skin-Cancer2019 will review and focus on the recent advancements in the diagnosis, treatment and management of various skin cancers such as basal and squamous cell carcinomas, melanoma, merkel cell carcinoma, cutaneous lymphomas and other rare

APR 5-7, Berlin, Germany: ESH How to Diagnose and Treat Multiple Myeloma

This meeting aims to present and debate the latest data and information in the field of Multiple Myeloma. This thought-provoking academic dialogue will address the most challenging current biology, clinical and therapeutic questions. The unique

APR 24-27, Paris, France: European Association of Dermato Oncology Congress 2019

EADO (European Association of Dermato-Oncology) is an independent non-profit organization dedicated to promote, coordinate and improve clinical and laboratory research activities in the field of skin cancer including primary and secondary

MAY 3-5, Paris, France: Controversies in Multiple Myeloma (COMy)

Over the last few years, the myeloma field has made significant progresses. We have seen fascinating novel drugs being introduced, and the whole treatment paradigm is progressively changing. Like the previous ones, this international meeting aims to

MAY 17, Leeds, UK: Melanoma Focus Regional Meeting UK

Melanoma Focus is a national charity dedicated to providing a comprehensive and authoritative source of information for public and professionals alike, as well as supporting education and promoting research about melanoma.

MAY 23, Utrecht, The Netherlands: BCF Career Event Netherlands

The ability to attract the best talent is essential for every organisation, but especially for companies in the Bio/Life Sciences, Chemistry, Food & Pharma (BCF) sector. More information? Please visit their website. 

MAY 31-4, Chicago IL, US: American Society of Clinical Oncology

ASCO 2019, 55th Annual Meeting of the American Society of Clinical Oncology is regarding Medical, Health, Breast Cancer, Oncology, Cancer, Medical Oncology, Cancer Treatment, Immunotherapy, Colorectal Cancer, Skin Cancer, Cancer Prevention, Melanoma,

JUN 10-15, Milan, Italy: World Congress of Dermatology

The Italian Society of Dermatology (SIDeMaST) is hosting the 24th World Congess of Dermatology (WCD) in Milan from June 10-15, 2019.

JUN 13-16, Amsterdam, The Netherlands: European Hematology Association Congress

The EHA Congress is a forum for original data, hematological innovation and evidence-based knowledge of primary clinical relevance. The congress also provides Satellite Symposia, Updates-in-Hematology and an exhibition organized by pharmaceutical

JUN 22, Terhulpen, Belgium: Post-ASCO Meeting Belgium & Luxembourg

Educational sessions cover state-of-the art treatment procedures and scientific and poster sessions offer a forum for a large number of high quality studies. Information is presented on promising experimental therapeutics. New strategies and old

SEP 11-14, Houston TX, US: Society of Hematologic Oncology (SOHO)

The Society of Hematologic Oncology (SOHO) was established as a non-profit corporation in 2012 with aims to promote worldwide research, education, prevention, clinical studies and optimal patient care in all aspects of hematologic

SEP 12-15, Boston MA, US: International Myeloma Workshop

The International Myeloma Workshops are the defining meetings in myeloma with a focus on both the basic, preclinical and the clinical aspects, including: Scientific Programs, Oral Presentations (on Basic Biology, Preclinical Trials and Clinical

SEP 27-1, Barcelona, Spain: European Society for Medical Oncology (ESMO) congress

The ESMO Congress is the appointment in Europe for clinicians, researchers, patient advocates, journalists and the pharmaceutical industry from all over the world to get together, learn about the latest advances in oncology and translate

OCT 9-13, Madrid, Spain: European Academy of Dermatology and Venereology (EADV) Congress

EADV is the leading community to further the knowledge of health professionals and advocates in the field of dermatology and venereology. They are dedicated to advancing patient care, education and research by providing a unique platform to

NOV 11-13, Hamburg, Germany: Annual International Partnering Conference BIO-EUROPE

Partnering event for the global biopharma industry.  

NOV 20-23, Salt Like City UT, US: 2019 Society for Melanoma Research Congress

The SMR holds annual meetings to provide researchers an opportunity to collaborate, meet, and share ideas about all forms of melanoma research.

DEC 7-10, Orlando FL, US: 61st ASH Annual Meeting & Exposition

The meeting will provide an invaluable educational experience and the opportunity to review thousands of scientific abstracts highlighting updates in the hottest topics in hematology. Network with top minds in the field and a global community of more